Hmmm good up date, awesome to have multiple expanded studies running parallel but looks like we wont get the autism data released until September, and the ADHD while a huge positive now expanded massively - is end of year, where as with the smaller trial we expected data sooner.
Story gets much stronger long term, short term , bit of a wait for news, so NFA but great buying on any dips back under 40c if we get there.
$I see this as $150ml MC in 2026 off the back of positive trial results for these studies, implied share price $1.50+ in 2026.
A nice 3x from current levels over 12-24 months. The amount spend and the wait times as we all know on these neurological issues, this is a future unicorn. A billy market cap if you have the patience. 3-5 years.
BB1 Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)